Advances in Prognostic Methylation Biomarkers for Prostate Cancer
نویسندگان
چکیده
منابع مشابه
Prognostic DNA methylation biomarkers in ovarian cancer.
PURPOSE Aberrant DNA methylation, now recognized as a contributing factor to neoplasia, often shows definitive gene/sequence preferences unique to specific cancer types. Correspondingly, distinct combinations of methylated loci can function as biomarkers for numerous clinical correlates of ovarian and other cancers. EXPERIMENTAL DESIGN We used a microarray approach to identify methylated loci...
متن کاملPrognostic DNA Methylation Markers for Prostate Cancer
Prostate cancer (PC) is the most commonly diagnosed neoplasm and the third most common cause of cancer-related death amongst men in the Western world. PC is a clinically highly heterogeneous disease, and distinction between aggressive and indolent disease is a major challenge for the management of PC. Currently, no biomarkers or prognostic tools are able to accurately predict tumor progression ...
متن کاملIdentification of prognostic biomarkers for prostate cancer.
PURPOSE This paper describes a process for the identification of genes that can report on the aggressiveness of prostate tumors and thereby add to the information provided by current pathologic analysis. MATERIALS AND METHODS Expression profiling data from over 100 laser capture microdissection derived samples from nonneoplastic epithelium; Gleason patterns 3, 4, and 5 and node metastasis pro...
متن کاملPrognostic biomarkers in early-stage prostate cancer.
EK There are 4 biopsy-based biomarker tests on the market for men who have not undergone surgery: Oncotype DX prostate cancer test from Genomic Health, Decipher Biopsy from GenomeDx, Prolaris from Myriad Genetics, and ProMark from Metamark Genetics (Table). The way they work is that a biopsy sample is sent to the company laboratory, which analyzes the expression of various genes in the prostate...
متن کاملAdvances in biomarkers for the early diagnosis of prostate cancer.
More and more studies have revealed that the level of serum prostate specific antigen(PSA) has little value for early diagnosis of prostate cancer (PCa). For example, negative prostate biopsies are as high as 70%-80% for patients with serum PSA ranging between 4 ng/mL and 10 ng/mL. However, the negative results cannot exclude the existence of cancer. In the studies of the early diagnosis of PCa...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancers
سال: 2020
ISSN: 2072-6694
DOI: 10.3390/cancers12102993